Canada Cough Hypersensitivity Syndrome Therapeutics Market Analysis

Canada Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The Canada Cough Hypersensitivity Syndrome Therapeutics Market is at around $0.648 Bn in 2022 and is projected to reach $1.025 Bn in 2030, exhibiting a CAGR of 5.9% during the forecast period.

Cough Hypersensitivity Syndrome (CHS) is marked by an enhanced response to stimuli, resulting in heightened sensitivity of the cough reflex. This sensitivity results in prolonged coughing caused by irritants such as dust, perfume, or cold air. Common causes of CHS include respiratory infections, gastroesophageal reflux disease (GERD), and exposure to environmental toxins. Symptoms usually include a chronic cough, which may be accompanied by throat irritation or pain. The treatment focuses on addressing the underlying causes and regulating the increased cough reflex. Antitussives, which suppress the cough reflex, and medicines to treat underlying problems like GERD are two possible treatment choices. Companies such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim are developing CHS treatments.

Cough Hypersensitivity Syndrome, which causes chronic cough, affects about 16% of Canadians. These estimates are amplified by increased risk factors like increased air pollution, smoking, and others. The market is being driven by significant factors such as the increase in the prevalence of Cough Hypersensitivity Syndrome, growing awareness and diagnosis, and the emergence of advanced therapeutics in the industry. However, conditions such as high costs of treatment, limited treatment options, and stringent regulations limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising prevalence of Cough Hypersensitivity Syndrome: CHS frequently occurs as a result of persistent respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. More than 16% of Canadians over the age of 45 suffer from chronic cough. The rising prevalence of these conditions in Canada is directly related to an increased pool of CHS patients requiring effective treatment options. Factors such as air pollution, smoking, and aging populations all contribute to the rise of chronic respiratory disorders, improving the potential for treating conditions like CHS.

Development of advanced therapeutics: CHS treatment is evolving as new drugs and therapies are used to control cough triggers and related mechanisms. This consists of P2X3 receptor antagonists, biologics, and combination therapies, which represent effective treatment alternatives. Pharmaceutical companies are investing significantly in the research and development of medications for CHS, resulting in a pipeline of candidates with the potential to drive market expansion.

Growing awareness and diagnosis: Growing awareness of CHS among healthcare professionals and patients leads to early diagnoses and prompt treatment. This enables timely intervention with therapeutics, resulting in market growth. Public health measures such as the National Lung Health Framework advances in diagnostic techniques, and a better understanding of CHS symptoms contribute to early diagnosis and management of the condition.

 Market Restraints

High costs of treatment: Several treatments, such as neuromodulators and P2X3 receptor antagonists, are classified as specialty drugs, which increases expenses for both patients and healthcare systems. This is a challenge for individuals, particularly those with low financial resources or inadequate insurance coverage.

Limited treatment options: Treatment alternatives, like cough suppressants, inhaled corticosteroids, and proton pump inhibitors (PPIs), focus on related problems such as GERD or asthma rather than the cough. Several existing drugs owing to their long-term usage have adverse effects resulting in treatment non-adherence, limiting the market growth

Regulatory hurdles: Developing therapies for CHS faces challenges due to regulatory requirements and a lengthy clinical trial procedure by Health Canada. These factors discourage pharmaceutical companies from investing in R&D for a small patient group.

Notable Updates

April 2023, GSK acquired Canada-based BELLUS Health for a total of $2 Bn. This acquisition gives GSK access to BELLUS's only medication in development, Camlipixant, a P2X3 antagonist that is now in Phase III for the initial treatment of adult patients with refractory chronic cough (RCC)

Healthcare Policies and Regulatory Landscape

In Canada, the principal regulatory body for therapeutics is Health Canada, specifically the Health Products and Food Branch (HPFB). The HPFB regulates pharmaceuticals, biologics, and medical devices to ensure that therapeutic goods available in Canada meet strict safety, efficacy, and quality criteria.

The procedure for gaining therapeutic product licensure in Canada is systematic. Companies have to submit a New Drug Submission (NDS) or a Biologics License Application (BLA), which includes detailed information about the product's efficacy. After completing the regulatory requirements, Health Canada issues a Notice of Compliance (NOC), allowing marketing authorization in Canada

The regulatory framework in Canada requires comprehensive review processes which present barriers for new entrants in the industry

Competitive Landscape

Key Players

• Johnson & Johnson
• Bayer AG
• Teva Canada Limited
• GlaxoSmithKline
• Pfizer
• Boehringer Ingelheim
• AstraZeneca
• F. Hoffman-La Roche Ltd
• Merck
• Novartis